EMA PRAC Assessment Report on Ondansetron Use in Pregnancy

An academic paper critiques the European Medicines Agency's 2019 assessment and updated labeling for the antiemetic drug ondansetron during the first trimester of pregnancy. The work analyzes the regulatory decision-making process, epidemiological study results, and the resulting clinical implications for treating severe nausea and vomiting of pregnancy. It was authored by Per Damkier from the University of Southern Denmark.

Use Cases

• Analyzing regulatory decision-making processes based on the detailed assessment of published data and supplementary questions to the Marketing Authorization Holder.
• Studying the association between first-trimester ondansetron use and birth defects based on the cited cohort study of 1.8 million pregnancies.
• Comparing conflicting results from epidemiological studies on cardiac malformations as discussed in the report.
• Examining the translation of pharmacovigilance assessments into clinical practice guidelines and product labeling changes.

Strengths

• Focuses on a specific, high-impact regulatory decision by the European Medicines Agency and its Pharmacovigilance Risk Assessment Committee.
• Cites a large-scale cohort study involving 1.8 million pregnancies to discuss risk associations.
• Provides a nuanced critique of the regulatory language and its potential consequences for clinical practice.

Limitations

• The dataset is a single academic paper; its scope is limited to the analysis and critique presented within the text.
• Row count, column definitions, and file formats for any underlying data are unknown.
• The last update date for the paper or its referenced data is unknown.

Provenance

Source

Per Damkier, University of Southern Denmark / Odense University Hospital

Collection Method

Academic analysis and critique of a published regulatory assessment report.

Time Range

Centered on the 2019 EMA/PRAC assessment and label update.

Geography

European Union (focus of the EMA assessment)